

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

**KINTOR PHARMACEUTICAL RECEIVED
FIRST EMERGENCY USE AUTHORISATION (EUA)
FOR PROXALUTAMIDE FOR THE TREATMENT OF
COVID-19 IN PARAGUAY**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**” together with its subsidiaries, the “**Group**” or “**Kintor Pharmaceutical**”) to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the “**Board**”) of directors (“**Director(s)**”) of the Company is pleased to announce that, the Ministry of Public Health and Social Welfare (MSPBS) of Paraguay recently granted emergency use authorisation (EUA) for proxalutamide for the treatment of hospitalised patients with COVID-19 at the MSPBS hospitals. This is the first EUA obtained for proxalutamide globally. The first hospital to use proxalutamide under the EUA, Hospital Barrio Obrero, part of Paraguay’s MSPBS network, has reported promising initial results.

Proxalutamide is a new-generation androgen receptor (AR) antagonist that is currently under development for the potential treatment of COVID-19 (including outpatients and inpatients), prostate cancer, and breast cancer. For the treatment of COVID-19, the Group is conducting multiple registered phase III multi-regional clinical trials (MRCT) in countries and regions including the United States, South America (including Brazil), the European Union, and Asia. The Group will advance the EUA applications for proxalutamide in other countries and regions as soon as possible and accelerate its commercialisation.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that proxalutamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 16, 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*